DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.

NCT Number	NCT07158164
Lead Sponsor	Rutgers, The State University of New Jersey
Conditions	Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
Enrollment	100 participants
Start Date	2025-08-27
Primary Completion	2027-07-07 (estimated)
Study Completion	2029-07-07 (estimated)
Updated on ClinicalTrials.gov	2025-11-13